BioSpace News Archive

Thermo Fisher Scientific Inc., the world leader in serving science, is providing proteomics and biopharmaceutical research laboratories with a new micro-pillar array column as part of an end-to-end LC-MS workflow that will simplify complex bottom-up proteomics analyses.

AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Lars Boesgaard, Chief Financial Officer, is scheduled to present at the Jefferies Healthcare Conference, being held in New York, NY on Wednesday, June 8th , 2022 at 8:00 AM ET.

Agilent Technologies Inc. (NYSE: A) today announced the release of its MassHunter BioConfirm 12.0 software, which now supports data generated by Agilent high-resolution LC/MS for oligonucleotide purity analysis and sequence confirmation.

Unprecedented accuracy of the company’s duplex sequencing technology continues to advance discovery in applications across medicine and life sciences.

Versant Ventures today announced it will file an early warning report with respect to the ownership of securities in Repare Therapeutics Inc.

Enzo Biochem, Inc., a leading biosciences and diagnostics company, announced that it will report third quarter 2022 financial results on Thursday, June 9, 2022, after the market close.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presents data on sleep disturbances in Parkinson’s disease (PD) demonstrating the impact of OFF episodes, or reemergence of symptoms between doses of levodopa, on falling asleep and staying asleep.

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Karen A. Flynn, Senior Vice President and Chief Commercial Officer of Catalent Pharma Solutions (NYSE: CTLT), has been appointed to Quanterix’ Board of Directors effective June 6, 2022.

Third Harmonic Bio, a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe allergy and inflammation, today announced the appointment of Edward R. Conner, M.D., to chief medical officer.

Pear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET ® at Six Months.